Cipla Limited (BSE: 500087; NSE: CIPLA EQ and hereafter referred to as ‘Cipla’) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).
Cipla’s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer’s Depo-Provera. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera and its generic equivalents had US sales of approximately $159M for the 12-month period ending November 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.